Personalized therapy in breast cancer

Systemic treatment of non-metastatic breast cancer is based on endocrine therapy, cytotoxic chemotherapy, and molecular targeted therapy - with the major problems of immense overtreatment of patients who would not relapse without systemic therapy and the failure of treatment in others whose disease...

Full description

Saved in:
Bibliographic Details
Main Authors: Marmé, Frederik (Author) , Schneeweiss, Andreas (Author)
Format: Article (Journal)
Language:English
Published: 2012
In: Onkologie
Year: 2012, Volume: 35, Pages: 28-33
ISSN:1423-0240
DOI:10.1159/000334973
Online Access:Verlag, Volltext: http://dx.doi.org/10.1159/000334973
Verlag, Volltext: https://www.karger.com/Article/FullText/334973
Get full text
Author Notes:Frederik Marmé, Andreas Schneeweiss
Description
Summary:Systemic treatment of non-metastatic breast cancer is based on endocrine therapy, cytotoxic chemotherapy, and molecular targeted therapy - with the major problems of immense overtreatment of patients who would not relapse without systemic therapy and the failure of treatment in others whose disease still recurs. These deficits can only be overcome by the identification of new and better prognostic and predictive markers. Currently, adjuvant treatment stratification is based on a limited number of established factors, namely locoregional tumour stage, age, grade, expression of hormone receptors, HER2, and Ki-67. Molecular profiling techniques, however, have revolutionized our understanding of breast cancer as a heterogeneous disease. Future results from even more comprehensive genetic analyses as part of the coordinated cancer genome projects will help to develop better treatment stratifications and new therapeutic approaches. Efforts to realize the dream of a personalized treatment for breast cancer will include drug development and intelligent design of trials for increasingly small subgroups of patients with specific host and disease characteristics. This will only be made possible by a strong cooperation between basic researchers and translational scientists, clinicians, as well as academia and industry.
Item Description:Published online: January 20, 2012
Gesehen am 05.10.2018
Physical Description:Online Resource
ISSN:1423-0240
DOI:10.1159/000334973